CR20200461A - METHOD TO TREAT HPV-ASSOCIATED DISEASES - Google Patents

METHOD TO TREAT HPV-ASSOCIATED DISEASES

Info

Publication number
CR20200461A
CR20200461A CR20200461A CR20200461A CR20200461A CR 20200461 A CR20200461 A CR 20200461A CR 20200461 A CR20200461 A CR 20200461A CR 20200461 A CR20200461 A CR 20200461A CR 20200461 A CR20200461 A CR 20200461A
Authority
CR
Costa Rica
Prior art keywords
hpv
associated diseases
associated disease
immune cells
treat hpv
Prior art date
Application number
CR20200461A
Other languages
Spanish (es)
Inventor
Scott Loughhead
Alfonso Vicente-Suarez
Howard Bernstein
Matt Booty
Lee Ann Talarico
Kelan Hlavaty
Armon R Sharei
Melissa Myint
Katarina Blagovic
Original Assignee
Sqz Biotechnologies Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sqz Biotechnologies Co filed Critical Sqz Biotechnologies Co
Publication of CR20200461A publication Critical patent/CR20200461A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by a specific adjuvant, e.g. cytokines or CpG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<p>The present application provides immune cells comprising an HPV antigen and an adjuvant, methods of manufacturing such modified immune cells, and methods of using such modified immune cells for treating an HPV-associated disease, preventing an HPV-associated disease and/or for modulating an immune response in an individual with an HPV-associated disease.</p>
CR20200461A 2018-03-12 2019-03-11 METHOD TO TREAT HPV-ASSOCIATED DISEASES CR20200461A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862641988P 2018-03-12 2018-03-12
US201962794517P 2019-01-18 2019-01-18
US201962812225P 2019-02-28 2019-02-28
PCT/US2019/021703 WO2019178005A2 (en) 2018-03-12 2019-03-11 Methods for treating hpv-associated diseases

Publications (1)

Publication Number Publication Date
CR20200461A true CR20200461A (en) 2021-03-11

Family

ID=65904594

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200461A CR20200461A (en) 2018-03-12 2019-03-11 METHOD TO TREAT HPV-ASSOCIATED DISEASES

Country Status (18)

Country Link
US (1) US12599656B2 (en)
EP (1) EP3765073A2 (en)
JP (1) JP2021517895A (en)
KR (1) KR20200130371A (en)
CN (1) CN112105383A (en)
AU (1) AU2019234549B2 (en)
BR (1) BR112020018609A2 (en)
CA (1) CA3093826A1 (en)
CO (1) CO2020012583A2 (en)
CR (1) CR20200461A (en)
IL (1) IL277190B2 (en)
MA (1) MA52003A (en)
MX (1) MX2020009441A (en)
PE (1) PE20201201A1 (en)
PH (1) PH12020551437A1 (en)
SG (1) SG11202008863XA (en)
TW (1) TW202003025A (en)
WO (1) WO2019178005A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
RU2770492C2 (en) 2016-05-03 2022-04-18 ЭсКьюЗед БАЙОТЕКНОЛОДЖИЗ КОМПАНИ Intracellular delivery of biological molecules for tolerance inducing
JP7595827B2 (en) * 2018-03-12 2024-12-09 ステムセル テクノロジーズ カナダ インコーポレーテッド Intracellular delivery of biomolecules to modify immune responses
MA52003A (en) 2018-03-12 2021-01-20 Sqz Biotechnologies Co TREATMENT METHODS FOR DISEASES ASSOCIATED WITH HPV
JP7610773B2 (en) * 2019-02-28 2025-01-09 ステムセル テクノロジーズ カナダ インコーポレーテッド Delivery of biomolecules to PBMCs to modify immune responses
KR20210149791A (en) 2019-04-08 2021-12-09 에스큐지 바이오테크놀로지스 컴퍼니 Cartridge for use in a system for delivering a payload into a cell
CN114375339A (en) 2019-05-14 2022-04-19 普罗米修斯生物科学公司 TL1A patient selection method, system and device
CN112007149A (en) * 2019-05-29 2020-12-01 思格(苏州)生物科技有限公司 Novel composite immunologic adjuvant and application thereof
CN110846318A (en) * 2019-11-29 2020-02-28 华中科技大学同济医学院附属同济医院 Novel targeting sequence in nanoparticle preparation for treating HPV infection and preparation method of new PBAE
CA3177288A1 (en) 2020-05-11 2021-11-18 F.Hoffmann-La Roche Ag Combination therapy with modified pbmcs and an immunoconjugate
CN116437950B (en) * 2020-07-24 2024-10-01 四川大学华西医院 An allogeneic B cell vaccine targeting EBV and preparation method thereof
EP4188425B1 (en) 2020-07-29 2025-05-14 Stemcell Technologies Canada Inc. Methods to stimulate immune responses to mutant ras using anucleate cells
WO2022026620A1 (en) 2020-07-29 2022-02-03 Sqz Biotechnologies Company Methods to stimulate immune responses to mutant ras using nucleated cells
WO2022051437A2 (en) * 2020-09-02 2022-03-10 Sqz Biotechnologies Company Methods to stimulate hla-agnostic immune responses to proteins using nucleated cells
WO2022147017A1 (en) 2020-12-29 2022-07-07 Sqz Biotechnologies Company Formulations for cryopreservation of pbmcs
CN116847880A (en) 2020-12-29 2023-10-03 Sqz生物技术公司 Formulations of activated antigen carriers
WO2022147026A1 (en) 2020-12-29 2022-07-07 Sqz Biotechnologies Company METHODS FOR TREATING CANCERS WITH MODIFIED PBMCs
JP2024501023A (en) * 2020-12-29 2024-01-10 スクイーズ バイオテクノロジーズ カンパニー Method for treating cancer using activated antigen carriers
WO2023010090A1 (en) 2021-07-29 2023-02-02 Sqz Biotechnologies Company Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery
CN118510888A (en) 2021-11-11 2024-08-16 加拿大干细胞技术公司 Methods for generating enhanced tumor-infiltrating lymphocytes by microfluidic delivery
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
EP4561615A2 (en) 2022-07-28 2025-06-04 Stemcell Technologies Canada Inc. Enhanced antigen presenting cell formulations
CA3262756A1 (en) 2022-07-28 2024-02-01 Stemcell Technologies Canada Inc. Methods for treating cancer with enhanced antigen presenting cells

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2502621C3 (en) 1975-01-23 1978-09-14 Kernforschungsanlage Juelich Gmbh, 5170 Juelich Measurement of elastic and dielectric properties of the membrane of living cells
US4376634A (en) 1980-05-30 1983-03-15 Mallinckrodt, Inc. Assay kit having syringe, dilution device and reagents within sealed container
FR2569477B1 (en) 1984-08-24 1987-01-02 Descartes Universite Rene APPARATUS AND METHOD FOR DETERMINING THE DEFORMABILITY OF RED BLOOD CELLS
JP2720161B2 (en) 1988-02-01 1998-02-25 株式会社アドバンス Cell deformability measuring device
JP2685544B2 (en) 1988-11-11 1997-12-03 株式会社日立製作所 Blood filter, blood test method, and blood test apparatus
JP2532707B2 (en) 1990-03-08 1996-09-11 佑二 菊池 Blood circuit, blood measuring apparatus and blood measuring method using the same
WO2002067863A2 (en) 2001-02-22 2002-09-06 The Scepens Eye Research Institute, Inc. Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions
WO2003020039A1 (en) 2001-08-28 2003-03-13 Rush-Presbyterian-St. Luke's Medical Center Immune tolerance to predetermined antigens
EP1411351A4 (en) 2002-06-05 2010-07-07 Panasonic Corp DEVICE FOR MEASURING AN EXTRACELLULAR POTENTIAL AND METHOD FOR MANUFACTURING THE SAME
US20060134067A1 (en) 2003-02-18 2006-06-22 Maxcyte, Inc. Loading of cells with antigens by electroporation
US20090028874A1 (en) 2003-12-24 2009-01-29 Leiden University Medical Center Synthetic Protein as Tumor-Specific Vaccine
CA2821167C (en) 2004-05-03 2016-06-28 Merrimack Pharmaceuticals, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
US7968335B2 (en) 2004-06-17 2011-06-28 Ken Nakata Cell culturing method using biomechanical stimulation loading and system therefor
ES2350895T3 (en) 2004-08-19 2011-01-28 University College Cardiff Consultants Limited PREPARATION OF T GAMMA DELTA HUMAN CELLS PRESENTING ANTIGENS AND ITS USE IN IMMUNOTHERAPY.
US20060134772A1 (en) 2004-11-18 2006-06-22 The Regents Of The University Of California System for locating cells and for cellular analysis
US7704743B2 (en) 2005-03-30 2010-04-27 Georgia Tech Research Corporation Electrosonic cell manipulation device and method of use thereof
PL1899364T5 (en) 2005-05-17 2024-12-09 University Of Connecticut Compositions and methods for immunomodulation in an organism
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
US8293524B2 (en) 2006-03-31 2012-10-23 Fluxion Biosciences Inc. Methods and apparatus for the manipulation of particle suspensions and testing thereof
US20070249038A1 (en) 2006-04-21 2007-10-25 Andrea Adamo Microfluidic device for single cell targeted operations
EP2054499A2 (en) 2006-08-17 2009-05-06 Massachusetts Institute of Technology Method and apparatus for microfluidic injection
WO2008046251A1 (en) * 2006-10-19 2008-04-24 Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. Fusion proteins containing n domain of human calreticulin and human papillomavirus type 16 e6 or e7 and uses thereof
WO2008098094A1 (en) 2007-02-06 2008-08-14 Network Biosystems, Inc. Devices and methods for the performance of miniaturized in vitro assays
US20080311140A1 (en) 2007-05-29 2008-12-18 Baylor College Of Medicine Antigen specific immunosuppression by dendritic cell therapy
AU2008269721B2 (en) 2007-05-31 2013-01-10 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal HPV peptide vaccination
FR2919804B1 (en) 2007-08-08 2010-08-27 Erytech Pharma COMPOSITION AND ANTI-TUMOR THERAPEUTIC VACCINE
GB0718160D0 (en) 2007-09-18 2007-10-24 Medical Res Council Methods
EP2216639A4 (en) 2007-11-28 2014-01-15 Konica Minolta Opto Inc Blood fluidity measurement apparatus and blood fluidity measurement method
US20090280518A1 (en) 2008-05-12 2009-11-12 Massachusetts Institute Of Technology System for high throughput measurement of mechanical properties of cells
JP5137129B2 (en) 2008-07-23 2013-02-06 国立大学法人山口大学 Measuring device for mechanical properties of blood cells
US9115340B2 (en) 2008-08-08 2015-08-25 Agency For Science Technology & Research Microfluidic continuous flow device
JP5797190B2 (en) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド Vaccine immunotherapy
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
US9364831B2 (en) 2009-08-08 2016-06-14 The Regents Of The University Of California Pulsed laser triggered high speed microfluidic switch and applications in fluorescent activated cell sorting
WO2011051346A1 (en) 2009-10-27 2011-05-05 Erytech Pharma Composition to induce specific immune tolerance
AU2010336424B2 (en) 2009-12-23 2013-06-13 Cytovera, Inc. A system and method for particle filtration
US20120064505A1 (en) 2010-03-22 2012-03-15 Massachusetts Institute Of Technology Measurement of material properties and related methods and compositions
ES2869155T3 (en) 2010-11-25 2021-10-25 Imnate Sarl Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
ES2764105T3 (en) 2011-10-17 2020-06-02 Massachusetts Inst Technology Intracellular administration
WO2013185032A1 (en) 2012-06-07 2013-12-12 President And Fellows Of Harvard College Nanotherapeutics for drug targeting
WO2014165707A2 (en) 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
CN110511960B (en) 2013-07-15 2023-05-23 美国卫生和人力服务部 Anti-human papillomavirus 16 E6 T cell receptor
SG10201801188XA (en) 2013-08-16 2018-03-28 Massachusetts Inst Technology Selective delivery of material to cells
RU2739794C2 (en) 2014-10-31 2020-12-28 Массачусетс Инститьют Оф Текнолоджи Delivery of biomolecules into cells of immune system
AU2015341926B2 (en) * 2014-11-04 2018-09-27 Vidamune B.V. Therapeutic HPV16 vaccines
JP6846345B2 (en) 2014-11-14 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー Destruction and field delivery of compounds and compositions to cells
AU2016206870B2 (en) 2015-01-12 2022-02-17 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
AU2016289530B2 (en) 2015-07-09 2021-05-06 Massachusetts Institute Of Technology Delivery of materials to anucleate cells
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
JP7046795B2 (en) 2015-09-04 2022-04-04 スクイーズ バイオテクノロジーズ カンパニー Intracellular delivery of biomolecules mediated by surfaces with pores
ES2964746T3 (en) 2015-12-30 2024-04-09 Celgene Corp Methods of production of T lymphocytes and T lymphocytes produced by the same
CN108779475A (en) 2016-01-12 2018-11-09 Sqz生物技术公司 Intracellular delivery of the complex
RU2747878C2 (en) 2016-05-03 2021-05-17 ЭсКьюЗед БАЙОТЕКНОЛОДЖИЗ КОМПАНИ Intracellular delivery of biomolecules for tolerance induction
RU2770492C2 (en) 2016-05-03 2022-04-18 ЭсКьюЗед БАЙОТЕКНОЛОДЖИЗ КОМПАНИ Intracellular delivery of biological molecules for tolerance inducing
US11422127B2 (en) 2016-12-07 2022-08-23 Albany Medical College Ex vivo antigen and adjuvant pulsed peripheral blood mononuclear cells as a screening platform for candidate novel vaccines and candidate antigens
CN106632694B (en) * 2017-01-24 2021-02-12 南京益康生物医药有限公司 Recombinant protein, pharmaceutical composition and application
JP2021507689A (en) 2017-12-05 2021-02-25 スクイーズ バイオテクノロジーズ カンパニー Intracellular delivery of biomolecules to modulate antibody production
JP2021506309A (en) 2017-12-20 2021-02-22 スクイーズ バイオテクノロジーズ カンパニー System for delivery of payload into cells
MA52003A (en) 2018-03-12 2021-01-20 Sqz Biotechnologies Co TREATMENT METHODS FOR DISEASES ASSOCIATED WITH HPV
JP7595827B2 (en) 2018-03-12 2024-12-09 ステムセル テクノロジーズ カナダ インコーポレーテッド Intracellular delivery of biomolecules to modify immune responses
US20210388390A1 (en) 2018-10-04 2021-12-16 Sqz Biotechnologies Company Intracellular delivery of biomolecules to enhance antigen presenting cell function
WO2020154696A1 (en) 2019-01-25 2020-07-30 Sqz Biotechnologies Company Anucleate cell-derived vaccines
JP7610773B2 (en) 2019-02-28 2025-01-09 ステムセル テクノロジーズ カナダ インコーポレーテッド Delivery of biomolecules to PBMCs to modify immune responses
KR20210149791A (en) 2019-04-08 2021-12-09 에스큐지 바이오테크놀로지스 컴퍼니 Cartridge for use in a system for delivering a payload into a cell

Also Published As

Publication number Publication date
US20210038709A1 (en) 2021-02-11
WO2019178005A2 (en) 2019-09-19
MX2020009441A (en) 2021-01-08
WO2019178005A3 (en) 2019-10-17
RU2020132524A (en) 2022-04-13
PH12020551437A1 (en) 2021-09-06
SG11202008863XA (en) 2020-10-29
TW202003025A (en) 2020-01-16
IL277190B2 (en) 2026-04-01
AU2019234549B2 (en) 2026-02-12
KR20200130371A (en) 2020-11-18
IL277190B1 (en) 2025-12-01
IL277190A (en) 2020-10-29
CO2020012583A2 (en) 2020-10-30
CN112105383A (en) 2020-12-18
MA52003A (en) 2021-01-20
PE20201201A1 (en) 2020-11-11
BR112020018609A2 (en) 2020-12-29
AU2019234549A1 (en) 2020-10-08
CA3093826A1 (en) 2019-09-19
US12599656B2 (en) 2026-04-14
JP2021517895A (en) 2021-07-29
EP3765073A2 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
PH12020551437A1 (en) Methods for treating hpv-associated diseases
EP4257199A3 (en) Humanized anti-human-pd-1 antibody
CR20210493A (en) DELIVERY OF BIOMOLECULES TO PBMCs TO MODIFY AN IMMUNE RESPONSE
EA201791443A1 (en) NATURAL KILLER CELLS AND THEIR APPLICATIONS
MX2015013065A (en) Prefusion rsv f proteins and their use.
GT201200318A (en) ANTIBODIES TO GDF8 HUMAN
EA201990293A1 (en) MULTI-SPECIFIC ANTIBODIES AGAINST CD40 AND CD137
MX2022006073A (en) Methods of use of anti-trem2 antibodies.
MX2022015631A (en) HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOF.
MX352338B (en) NEUTRALIZING ANTIBODIES OF THE INFLUENZA A VIRUS AND USES OF THESE.
AR094740A1 (en) ANTIADHESION OF LEUKOCYTES TO MITIGATE POTENTIAL ADVERSE EVENTS CAUSED BY CD3 SPECIFIC UNION DOMAINS
EA201691473A1 (en) BISPECIFIC ANTI-IL-13 / IL-17 ANTIBODIES AND THEIR APPLICATION
JOP20190055A1 (en) Anti-cd27 antibodies
MX2016009189A (en) Immunity enhancing therapeutic vaccine for hpv and related diseases.
EA201892190A1 (en) TREATMENT OF PSORIASIS WITH ANTI-BODY TO IL-12 AND / OR IL-23 WITH THE GROWTH OF THE INTERVAL BETWEEN THE INTRODUCTION OF DOSE
MX2020010913A (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs.
MX2017007187A (en) Dna antibody constructs and method of using same.
MX2021000853A (en) INDIVIDUALIZED VACCINES FOR CANCER.
EA201990010A1 (en) INFECTIOUS Bronchitis Virus Vaccine
ZA202205927B (en) Anti-yellow fever virus antibodies, and methods of their generation and use
AR105541A1 (en) SPECIFIC MONOCLONAL ANTIBODIES FOR THE ANTIGEN P OF THE HUMAN SYNCHRIRY RESPIRATORY VIRUS (VRSh), PRODUCED AND SECRETED BY CELLULAR HYBRIDIDES, USEFUL FOR THE DETECTION AND DIAGNOSIS OF THE INFECTION CAUSED BY VRS
CL2016002827A1 (en) Systems, methods and kits for cleansing an ocular region
EA202192923A1 (en) ANTIBODIES AND METHODS OF TREATMENT OF INFLUENZA A VIRUS INFECTION
MX2021010061A (en) FC FUSION PROTEINS WITH EXTRACELLULAR DOMAIN OF CD80 TO TREAT PD-L1 NEGATIVE TUMORS.
EA202090260A1 (en) MEANS AND METHODS FOR HUMAN AAV GENOTHERAPY